<DOC>
	<DOCNO>NCT02362074</DOCNO>
	<brief_summary>The purpose study describe impact treatment adalimumab work relate productivity economic burden patient Rheumatoid Arthritis ( RA ) treat Canada .</brief_summary>
	<brief_title>Progress Work - The Impact Adalimumab Work Related Productivity Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subjects moderate severe RA physician decide initiate treatment adalimumab 2 . Adult male female â‰¥ 18 year old newly prescribe adalimumab therapy accord local product label PROGRESS 3 . Subjects evaluate tuberculosis ( TB ) exposure/risk factor active latent TB 4 . Subject able give write patient authorization willing comply requirement study protocol . 1 . Subject sign patient authorization 2 . Subject know hypersensitivity Adalimumab , components 3 . Presence condition , opinion treat physician , prohibits subject participate study obscures assessment treatment RA 4 . Subjects currently participate investigational clinical trial 5 . Subjects treat &gt; 1 prior biologic diseasemodifying antirheumatic drug ( DMARDs ) RA . Any prior treatment adalimumab prohibit 6 . Subjects previously treat target synthetic disease modify agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>